Express News | Capricor Therapeutics Files Prospectus Relates to Resale by Selling Stockholder of up to 2.8 Mln Shares of Common Stock -SEC Filing
Capricor Therapeutics Analyst Ratings
Retail Investors Account for 45% of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Ownership, While Institutions Account for 14%
Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35
Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships
Express News | Capricor Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $35